Telix Recognised by the Australian Financial Review as Australia’s Highest Achieving Company for International Growth
Melbourne (Australia) | 13 June 2023
Telix has today been recognised as Australia’s highest achieving company for international growth in the Australian Financial Review’s inaugural Fast Global list.
Fast Global celebrates Australian companies that are delivering real commercial growth in international markets, calculated on growth in revenue generated outside of Australia over the past three years.
Telix’s growth has been driven by the commercial revenue from its first approved product, Illuccix for prostate cancer imaging, which has been approved by the U.S. Food and Drug Administration and has been fully reimbursed in the U.S. since 1 July 2022.
With international revenue growing at a compound annual growth rate (CAGR) of 454% over the last three financial years, Telix has placed 1st on the list for 2023.
Building on the successful commercial launch of Illuccix® for prostate cancer imaging in the U.S., as well as here in Australia, we look forward to rolling out this product globally subject to regulatory approvals, and advancing other pipeline assets, positively impacting the lives of patients worldwide through Australian-led innovation.
Read more about Telix’s growth in the Australian Financial Review here.